Cefepime
Lee B. Barradell, Harriet M. Bryson · Drugs · 1994
Cited by 159 works. doi:10.2165/00003495-199447030-00007
Authors
References
- Extended Broad-Spectrum -Lactamases Conferring Transferable Resistance to Newer -Lactam Agents in Enterobacteriaceae: Hospital Prevalence and Susceptibility Patterns
- Outer membrane barrier as a mechanism of antimicrobial resistance
- Activities of beta-lactam antibiotics against Escherichia coli strains producing extended-spectrum beta-lactamases
- Microbial Resistance to Newer Generation f3-lactam Antibiotics: Clinical and Laboratory Implications
- From the Immunocompromised Host Society: The Design, Analysis, and Reporting of Clinical Trials on the Empirical Antibiotic Management of the Neutropenic Patient: Report of a Consensus Panel
- Comparison of a new cephalosporin, BMY 28142, with other broad-spectrum beta-lactam antibiotics
- Type I -Lactamases of Gram-Negative Bacteria: Interactions with -Lactam Antibiotics
- Pharmacokinetics of cefepime in subjects with renal insufficiency
- Cefepime: the next generation?
- Evaluation of the in vitro activity of BMY-28142, a new broad-spectrum cephalosporin